{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:30:16Z","timestamp":1793392216978,"version":"4.5.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100007404","name":"Clinical Trials Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007404","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021071","name":"Faculty of Medicine and Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"The University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Colchicine has recently been approved for the treatment of atherosclerotic cardiovascular disease (ASCVD). Since then, three large trials of colchicine in ASCVD have failed to reach their primary endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Embase and Cochrane Central Register of Controlled Trials was performed (PROSPERO registration: CRD42024616378). The primary endpoint of major adverse cardiovascular events (MACE) was defined as a composite of myocardial infarction (MI), stroke and cardiovascular death. The key secondary endpoint of extended MACE (eMACE) was defined as MACE plus coronary revascularisation. Pooled estimates were calculated using a random-effects model and are presented as risk ratio [95% confidence interval (CI)]. 1624 articles were screened. 12 met inclusion criteria, yet one trial reported zero endpoint events in both arms. As such, 11 trials were included in the meta-analysis, with a total of 1983 primary endpoint events across 30 808 participants. Colchicine was associated with a 17% reduction in the incidence of MACE [0.83 (0.73, 0.95); P = 0.006] and 23% reduction in the incidence of eMACE [0.77 (0.63, 0.94); P = 0.01]. This reduction was driven by a lower rate of MI [0.78 (0.63, 0.95); P = 0.02] and coronary revascularisation [0.73 (0.55, 0.97); P = 0.03]. There were also numerically fewer strokes in the colchicine-treated population [0.81 (0.63, 1.04); P = 0.11]. Colchicine had no effect on cardiovascular [0.96 (0.79, 1.15); P = 0.64] or non-cardiovascular mortality [1.04 (0.76, 1.41); P = 0.81].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Colchicine reduces the risk of non-fatal ischaemic events in patients with ASCVD. Further studies are required to identify a population(s) who stands to benefit most from this promising therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf302","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T08:23:55Z","timestamp":1747297435000},"page":"694-704","source":"Crossref","is-referenced-by-count":22,"title":["The efficacy and safety of low dose colchicine in atherosclerotic cardiovascular disease: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7028-4331","authenticated-orcid":false,"given":"Bradley","family":"Tucker","sequence":"first","affiliation":[{"name":"Department of Cardiology, Royal Prince Alfred Hospital , Camperdown, NSW ,","place":["Australia"]},{"name":"Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney , Camperdown, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Tucker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Tweed Valley Hospital , Cudgen, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Soo","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal Prince Alfred Hospital , Camperdown, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma A","family":"Figtree","sequence":"additional","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health, University of Sydney , Sydney, NSW ,","place":["Australia"]},{"name":"Cardiovascular Discovery Group, Kolling Institute of Medical Research , St Leonards, NSW ,","place":["Australia"]},{"name":"Department of Cardiology, Royal North Shore Hospital , St Leonards, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Keech","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal Prince Alfred Hospital , Camperdown, NSW ,","place":["Australia"]},{"name":"Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney , Camperdown, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal Prince Alfred Hospital , Camperdown, NSW ,","place":["Australia"]},{"name":"Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney , Camperdown, NSW ,","place":["Australia"]},{"name":"Coronary Diseases Group, Heart Research Institute , Newtown, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"2026032619563423200_zwaf302-B1","first-page":"618","article-title":"Colchicine in atherosclerotic cardiovascular disease","volume":"110","author":"Tucker","year":"2024","journal-title":"Heart"},{"key":"2026032619563423200_zwaf302-B2","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1042\/CS20160090","article-title":"Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation","volume":"130","author":"Robertson","year":"2016","journal-title":"Clin Sci (Lond"},{"key":"2026032619563423200_zwaf302-B3","doi-asserted-by":"crossref","first-page":"e22846","DOI":"10.1096\/fj.202201469R","article-title":"Colchicine exerts anti-atherosclerotic and -plaque-stabilizing effects targeting foam cell formation","volume":"37","author":"Schwarz","year":"2023","journal-title":"Faseb j"},{"key":"2026032619563423200_zwaf302-B4","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.clinthera.2019.07.015","article-title":"Colchicine as a novel therapy for suppressing chemokine production in patients with an acute coronary syndrome: a pilot study","volume":"41","author":"Tucker","year":"2019","journal-title":"Clin Ther"},{"key":"2026032619563423200_zwaf302-B5","doi-asserted-by":"crossref","first-page":"e018993","DOI":"10.1161\/JAHA.120.018993","article-title":"Colchicine inhibits neutrophil extracellular trap formation in patients with acute coronary syndrome after percutaneous coronary intervention","volume":"10","author":"Vaidya","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026032619563423200_zwaf302-B6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","article-title":"Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study","volume":"11","author":"Vaidya","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026032619563423200_zwaf302-B7","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur Heart J"},{"key":"2026032619563423200_zwaf302-B8","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2026032619563423200_zwaf302-B9","doi-asserted-by":"crossref","first-page":"e079061","DOI":"10.1136\/bmj-2023-079061","article-title":"Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial","volume":"385","author":"Li","year":"2024","journal-title":"BMJ"},{"key":"2026032619563423200_zwaf302-B10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"key":"2026032619563423200_zwaf302-B11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(24)00968-1","article-title":"Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial","volume":"404","author":"Kelly","year":"2024","journal-title":"The Lancet"},{"key":"2026032619563423200_zwaf302-B12","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026032619563423200_zwaf302-B13","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026032619563423200_zwaf302-B14","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/s12872-021-02393-9","article-title":"Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial","volume":"21","author":"Akrami","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"2026032619563423200_zwaf302-B15","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jacc.2013.01.055","article-title":"Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients","volume":"61","author":"Deftereos","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026032619563423200_zwaf302-B16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bcp.16270","article-title":"Colchicine effect on biomarkers of cardiac remodelling and atherosclerosis in ST-elevation myocardial infarction: a randomized controlled trial","volume":"91","author":"Hassanain","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"2026032619563423200_zwaf302-B17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf Stefan","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026032619563423200_zwaf302-B18","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2026032619563423200_zwaf302-B19","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/cvr\/cvae191","article-title":"Optical coherence tomography assessment of the impact of colchicine on non-culprit coronary plaque composition after myocardial infarction","volume":"121","author":"Psaltis","year":"2024","journal-title":"Cardiovasc Res"},{"key":"2026032619563423200_zwaf302-B20","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2026032619563423200_zwaf302-B21","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"2026032619563423200_zwaf302-B22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.124.069808","article-title":"Effect of colchicine on coronary plaque stability in acute coronary syndrome as assessed by optical coherence tomography: the COLOCT randomized clinical trial","volume":"150","author":"Yu","year":"2024","journal-title":"Circulation"},{"key":"2026032619563423200_zwaf302-B23","doi-asserted-by":"crossref","first-page":"102835","DOI":"10.1016\/j.eclinm.2024.102835","article-title":"Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials","volume":"76","author":"Fiolet","year":"2024","journal-title":"eClinicalMedicine"},{"key":"2026032619563423200_zwaf302-B24","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026032619563423200_zwaf302-B25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ahj.2019.06.003","article-title":"The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction","volume":"215","author":"Hennessy","year":"2019","journal-title":"Am Heart J"},{"key":"2026032619563423200_zwaf302-B26","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"The Lancet"},{"key":"2026032619563423200_zwaf302-B27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"2026032619563423200_zwaf302-B28","doi-asserted-by":"crossref","first-page":"104966","DOI":"10.1016\/j.healthpol.2023.104966","article-title":"How to increase COVID-19 vaccination among a population with persistently suboptimal vaccine uptake? Evidence from the North Macedonia mobile vaccination and public health advice caravan","volume":"139","author":"Serrano-Alarc\u00f3n","year":"2024","journal-title":"Health Policy"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf302\/63212480\/zwaf302.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/5\/694\/63212480\/zwaf302.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/5\/694\/63212480\/zwaf302.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:56:41Z","timestamp":1774569401000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/5\/694\/8133930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,16]]},"published-print":{"date-parts":[[2026,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf302","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,5,16]]}}}